Healthcare - Drug Manufacturers - Specialty & Generic - NASDAQ - IS
$ 11.73
-2.82 %
$ 3.54 B
Market Cap
-4.55
P/E
CASH FLOW STATEMENT
-312 M
OPERATING CASH FLOW
-46.3 M
INVESTING CASH FLOW
301 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Alvotech
| Net Income | -552 M |
| Depreciation & Amortization | 24.2 M |
| Capital Expenditures | -46.5 M |
| Stock-Based Compensation | 18 M |
| Change in Working Capital | 26.3 M |
| Others | 306 M |
| Free Cash Flow | -359 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||
| Net Income | (551.7) | (513.6) | (101.5) | (170.0) | (209.9) |
| Depreciation & Amortization | 24.2 | 20.4 | 18.2 | 16.4 | 14.6 |
| Deferred Income Tax | (99.3) | (38.1) | (47.7) | (121.7) | 0.5 |
| Stock Based Compensation | 18.0 | 10.3 | 0 | 0 | 22.3 |
| Other Operating Activities | 270.3 | 256.4 | (68.0) | 174.0 | 128.9 |
| Change in Working Capital | 26.3 | (47.9) | (6.8) | 32.5 | (13.8) |
| Cash From Operations | (312.2) | (312.4) | (228.2) | (74.3) | (88.5) |
| INVESTING CASH FLOW | |||||
| Capital Expenditures | (46.5) | (49.0) | (40.6) | (12.0) | (8.1) |
| Other Items | 0.1 | (14.5) | 0 | (4.9) | (4.8) |
| Cash From Investing Activities | (46.3) | (63.5) | (40.6) | (16.9) | (12.9) |
| FINANCING CASH FLOW | |||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 171.2 | 257.8 | 69.0 | 21.0 | 85.7 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 130.1 | 167.1 | 0 | 34.4 | 30.7 |
| Cash From Financing Activities | 301.3 | 424.9 | 254.8 | 55.4 | 116.4 |
| CHANGE IN CASH | |||||
| Net Change In Cash | (55.3) | 48.9 | (14.1) | (35.7) | 15.2 |
| FREE CASH FLOW | |||||
| Free Cash Flow | (358.7) | (361.4) | (268.8) | (86.3) | (96.6) |